ERBB2 and breast cancer: Therefore, a comprehensive molecular understanding of the pathways associated with resistance to trastuzumab and chemotherapy might greatly aid the development of more effective targeted therapies, whereas the discovery of clinical molecular predictors of response will allow a more personalized treatment approach for patients with HER2-amplified breast cancer.